Please provide your email address to receive an email when new articles are posted on . Umpierrez and colleagues conducted a multicenter, prospective, open-label, randomized trial with 150 adults who ...

Investigational GLP-1 Treatment Improved Glucose Control with Just One Dose per Month SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: ...

Dr. Jay Skyler answers the question: 'What Is Exenatide And When Is It Used?' — -- Question: What is exenatide and when is it used? Answer: Exenatide, or Byetta, is a synthetic peptide that acts ...

Treatment with the diabetes drug exenatide was associated with a significant decrease in hyperglycemia in acute stroke patients, a new study shows. The research could offer clinicians an alternative ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In patients with very poorly controlled type 2 diabetes ...

SAN DIEGO--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced additional results from a phase 2 study of ...

Findings showed MDS-UPDRS OFF medication scores had worsened (increased) by 5.7 points in exenatide-treated patients compared with a 4.5 point increase with placebo. Treatment with once-weekly ...

A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson’s disease, a new UCL-led study suggests, paving the way for further research to define its efficacy and ...

The Annals of Pharmacotherapy. 2012;46(6):812-821. Results of DURATION-1 demonstrated significantly greater reductions in A1C and a significantly greater proportion of patients achieving an A1C goal ...

(HealthDay News) — For patients with type 2 diabetes, the incidence of major cardiovascular events is similar for those receiving exenatide or placebo, according to a study published online in the New ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest trial ...

The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also assessed exenatide once weekly (exenatide extended-release for ...